fanconi anemia complementation group g
|
0.700 |
Biomarker
|
disease |
CLINGEN |
Fanconi anaemia and cancer: an intricate relationship.
|
29376519 |
2018 |
Fanconi Anemia
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
A strategy for molecular diagnostics of Fanconi anemia in Brazilian patients.
|
28717661 |
2017 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Founder haplotype analysis of Fanconi anemia in the Korean population finds common ancestral haplotypes for a FANCG variant.
|
25703136 |
2015 |
Fanconi Anemia
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Founder haplotype analysis of Fanconi anemia in the Korean population finds common ancestral haplotypes for a FANCG variant.
|
25703136 |
2015 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results showed that patients, homozygous for the FANCG founder mutation, present with severe cytopenia but progress to bone marrow failure at similar ages to other individuals affected with FA of heterogeneous genotype.
|
25477267 |
2015 |
fanconi anemia complementation group g
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Targeted resequencing of 52 bone marrow failure genes in patients with aplastic anemia reveals an increased frequency of novel variants of unknown significance only in SLX4.
|
24763404 |
2014 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study shows that mutations in FANCA and FANCG are common in Korean FA patients and the existence of four common founder mutations in an East Asian FA population.
|
23067021 |
2013 |
fanconi anemia complementation group g
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.
|
23613520 |
2013 |
Fanconi Anemia
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Diagnosis of Fanconi Anemia: Mutation Analysis by Multiplex Ligation-Dependent Probe Amplification and PCR-Based Sanger Sequencing.
|
22778927 |
2012 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
FANCG is one of Fanconi anemia susceptibility genes that participate in DSB repair pathway to prevent chromosomal aberrations.
|
21750350 |
2011 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
FANCA and FANCG are members of the FA core complex for which no other functions have been described than to participate in protein interactions.
|
22036606 |
2011 |
fanconi anemia complementation group g
|
0.700 |
Biomarker
|
disease |
CLINGEN |
Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia.
|
20606166 |
2010 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
How the fanconi anemia pathway guards the genome.
|
19686080 |
2009 |
fanconi anemia complementation group g
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
How the fanconi anemia pathway guards the genome.
|
19686080 |
2009 |
fanconi anemia complementation group g
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
HES1 is a novel interactor of the Fanconi anemia core complex.
|
18550849 |
2008 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
After successful mono-allelic deletion of all genes, the sequential homozygous deletion was achieved only for FANCC and FANCG, acting upstream, but not for BRCA2 or FANCD2, acting downstream in the FA pathway.
|
17387268 |
2007 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
We investigated a possible role for the Fanconi anemia (FA) pathway in particulate Cr(VI)-induced chromosomal damage by focusing on the Fancg gene, which plays an important role in cellular resistance to DNA interstrand crosslinks.
|
17097336 |
2007 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Given that FANCA, FANCC, and FANCG complementation groups account for more than 90% of all FA patients, these data provide evidence that IFN-gamma conditioning may be a useful nongenotoxic strategy for myelopreparation in FA patients.
|
16946306 |
2006 |
Fanconi Anemia
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Molecular pathogenesis of Fanconi anemia: recent progress.
|
16493006 |
2006 |
fanconi anemia complementation group g
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Molecular pathogenesis of Fanconi anemia: recent progress.
|
16493006 |
2006 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Two retrovirally complemented pancreatic cancer cell lines having defects in the Fanconi anemia pathway, PL11 (FANCC-mutated) and Hs766T (FANCG-mutated), as well as several parental pancreatic cancer cell lines with or without mutations in the Fanconi anemia/BRCA2 pathway, were assayed for in vitro and in vivo sensitivities to various chemotherapeutic agents.
|
16243825 |
2005 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the birth incidence of FA in this population is higher than 1 in 40 000, which is much higher than previously supposed, and suggest that the FANCG deletion is an ancient founder mutation in Bantu-speaking populations of sub-Saharan Africa.
|
15657175 |
2005 |
fanconi anemia complementation group g
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
A common Fanconi anemia mutation in black populations of sub-Saharan Africa.
|
15657175 |
2005 |
Fanconi Anemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since carriers of germline BRCA2 gene mutations have an increased risk of developing pancreatic cancer, the FA pathway has been investigated as a tumor suppressor pathway in pancreatic cancer.Recently van der Heijden et al. identified FANCC and FANCG gene mutations in patients with young-onset pancreatic cancer.
|
14726700 |
2004 |
Fanconi Anemia
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Our observations indicate that accelerated telomere shortening in patients with FA is not due to a role of FANCG at telomeres but instead may be secondary to the disease.
|
15319283 |
2004 |